Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Cash (2016 - 2025)

Historic Change in Cash for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to -$16.9 million.

  • Cartesian Therapeutics' Change in Cash fell 11283.62% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.7 million, marking a year-over-year decrease of 15414.94%. This contributed to the annual value of $136.0 million for FY2024, which is 55711.26% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported Change in Cash of -$16.9 million as of Q3 2025, which was down 11283.62% from -$20.0 million recorded in Q2 2025.
  • Over the past 5 years, Cartesian Therapeutics' Change in Cash peaked at $132.0 million during Q3 2024, and registered a low of -$34.0 million during Q3 2023.
  • Over the past 5 years, Cartesian Therapeutics' median Change in Cash value was -$6.6 million (recorded in 2024), while the average stood at $266052.6.
  • Examining YoY changes over the last 5 years, Cartesian Therapeutics' Change in Cash showed a top increase of 709883.04% in 2022 and a maximum decrease of 98928.57% in 2022.
  • Quarter analysis of 5 years shows Cartesian Therapeutics' Change in Cash stood at -$588000.0 in 2021, then plummeted by 989.29% to -$6.4 million in 2022, then soared by 57.97% to -$2.7 million in 2023, then plummeted by 144.73% to -$6.6 million in 2024, then crashed by 157.13% to -$16.9 million in 2025.
  • Its last three reported values are -$16.9 million in Q3 2025, -$20.0 million for Q2 2025, and -$32.2 million during Q1 2025.